[go: up one dir, main page]

PE20220133A1 - Inhibidores del inflamasoma nlrp3 - Google Patents

Inhibidores del inflamasoma nlrp3

Info

Publication number
PE20220133A1
PE20220133A1 PE2021001881A PE2021001881A PE20220133A1 PE 20220133 A1 PE20220133 A1 PE 20220133A1 PE 2021001881 A PE2021001881 A PE 2021001881A PE 2021001881 A PE2021001881 A PE 2021001881A PE 20220133 A1 PE20220133 A1 PE 20220133A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
independently selected
substituents independently
ethylpiperidin
Prior art date
Application number
PE2021001881A
Other languages
English (en)
Inventor
Nina Gommermann
Christopher Farady
Philipp Janser
Angela Mackay
Henri Mattes
Nichola Smith
Solovay Catherine Fooks
Nikolaus Johannes Stiefl
Eric Vangrevelinghe
Juraj Velcicky
Matt Anette Von
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20220133A1 publication Critical patent/PE20220133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Referida a un compuesto de la formula (I) o una sal farmaceuticamente aceptable del mismo, en donde R1 es Cl, CH3, -OCF3, o CF3; R2 es H, halo, alquilo C1-C4, o halo alquilo C1-C4; R3 , R4 son H, CN, alquilo C1-C4, o halo alquilo C1-C4; Z es -O-, o -NH-(CH2)n-, en donde n es 0, 1, o 2; R5 es un heterociclilo mono o biciclico, opcionalmente sustituido con 1 a 2 sustituyentes independientemente seleccionados entre alquilo C1-C4, halo alquilo C1-C4, hidroxi alquilo C1- C4, -OH, halo, oxo, y -CO2H; o R5 es un arilo o heteroarilo, opcionalmente sustituido con 1 a 2 sustituyentes independientemente seleccionados entre halo, halo alquilo C1-C4, alquilo C1-C4, y -SO2NH2; o R5 es cicloalquilo C3-C6 opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados entre alquilo C1-C4, halo, halo alquilo C1-C4, y -OH; o R5 es alquilo C2-C6 sustituido con 1 o mas sustituyentes independientemente seleccionados entre -OH, alcoxi C1-C4, halo, -NH2, -NH(alquilo C1-C4), y -N(alquilo C1-C4)2. Son compuestos preferidos: 2-(6-((1-Etilpiperidin-3-il)amino)piridazin-3-il)-3-metil-5-(trifluorometil) fenol; (S)-2-(6-((1-Etilpiperidin-3-il)amino)piridazin-3-il)-3-metil-5-(trifluorometil) fenol; (R)-2-(6-((1-Etilpiperidin-3-il)amino)piridazin-3-il)-3-metil-5-(trifluorometil) fenol; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos inhiben la actividad del inflamasoma de la proteina 3 del receptor tipo NOD (NLRP3).
PE2021001881A 2019-05-17 2020-05-15 Inhibidores del inflamasoma nlrp3 PE20220133A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962849245P 2019-05-17 2019-05-17
PCT/IB2020/054613 WO2020234715A1 (en) 2019-05-17 2020-05-15 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
PE20220133A1 true PE20220133A1 (es) 2022-01-27

Family

ID=70779818

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001881A PE20220133A1 (es) 2019-05-17 2020-05-15 Inhibidores del inflamasoma nlrp3

Country Status (26)

Country Link
US (4) US11208399B2 (es)
EP (1) EP3969441A1 (es)
JP (2) JP7558975B2 (es)
CN (2) CN119732956A (es)
AR (1) AR119731A1 (es)
AU (1) AU2020277738B2 (es)
BR (1) BR112021022796A2 (es)
CA (1) CA3138226A1 (es)
CL (1) CL2021003012A1 (es)
CO (1) CO2021015030A2 (es)
CR (1) CR20210552A (es)
CU (1) CU20210094A7 (es)
DO (1) DOP2021000228A (es)
EC (1) ECSP21080740A (es)
IL (1) IL287042B2 (es)
JO (1) JOP20210307A1 (es)
MX (1) MX2021013941A (es)
MY (1) MY206068A (es)
PE (1) PE20220133A1 (es)
PH (1) PH12021552885A1 (es)
SA (1) SA521430853B1 (es)
SG (1) SG11202111029PA (es)
TW (1) TWI874398B (es)
UY (1) UY38687A (es)
WO (1) WO2020234715A1 (es)
ZA (1) ZA202107444B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2021193897A1 (ja) 2020-03-27 2021-09-30 アステラス製薬株式会社 置換ピリダジン化合物
US20240092819A1 (en) * 2020-10-20 2024-03-21 Sanofi Novel ligands for asialoglycoprotein receptor
CN116507608A (zh) * 2020-11-20 2023-07-28 戴纳立制药公司 化合物、组合物和方法
CN116390914A (zh) * 2020-12-25 2023-07-04 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
US20240166610A1 (en) * 2021-02-08 2024-05-23 Medshine Discovery Inc. Substituted pyridazine phenol derivatives
JP2024508017A (ja) 2021-03-04 2024-02-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３を調節する４－アルコキシ－６－オキソ－ピリダジン誘導体
EP4301754A1 (en) 2021-03-04 2024-01-10 Janssen Pharmaceutica NV 4-amino-6-oxo-pyridazine derivatives modulating nlrp3
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN117222626A (zh) 2021-04-28 2023-12-12 安斯泰来制药株式会社 取代三嗪化合物
RS66893B1 (sr) 2021-05-12 2025-07-31 Hoffmann La Roche Inhibitori nlrp3
EP4347571A1 (en) 2021-06-04 2024-04-10 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer
US20240294542A1 (en) * 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
JP2024529839A (ja) * 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
WO2023275366A1 (en) 2021-07-02 2023-01-05 Astrazeneca Ab Nlrp3 inflammasome inhibitors
MX2024000984A (es) 2021-07-21 2024-06-19 Nico Therapeutics Inc Compuesto de piridazina anilado.
MX2024002342A (es) 2021-08-25 2024-05-20 Ptc Therapeutics Inc Inhibidores del nlrp3.
WO2023028536A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2023088856A1 (en) * 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
WO2023088987A1 (en) 2021-11-19 2023-05-25 F. Hoffmann-La Roche Ag Pyridazine derivatives as inhibitors of nlrp3
US20250074888A1 (en) * 2021-12-29 2025-03-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
AU2023205375A1 (en) * 2022-01-07 2024-07-18 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and uses thereof
CN119137121A (zh) * 2022-03-25 2024-12-13 万特斯治疗美国公司 可用作NLRP3衍生物的吡啶并-[3,4-d]哒嗪胺衍生物
LU501764B1 (en) 2022-03-31 2023-10-02 Leibniz Inst Fuer Naturstoff Forschung Und Infektionsbiologie E V Hans Knoell Inst Hki Gasdermin e expression in human t cells as a marker for proinflammatory t cell functions
EP4499646A1 (en) * 2022-03-31 2025-02-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
AR129012A1 (es) * 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
CN119546586A (zh) * 2022-05-13 2025-02-28 纽摩拉治疗公司 Nlrp3炎症小体的调节剂和相关产品以及方法
TW202409013A (zh) * 2022-05-13 2024-03-01 美商凡特斯治療美國公司 用於抑制ｎｌｒｐ３之側氧基吲哚啉基醯胺衍生物及其用途
CN119300833A (zh) * 2022-06-03 2025-01-10 豪夫迈·罗氏有限公司 新颖化合物
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN119546599A (zh) * 2022-07-14 2025-02-28 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
CN119585271A (zh) * 2022-07-21 2025-03-07 豪夫迈·罗氏有限公司 Nlrp3抑制剂
KR20250044368A (ko) 2022-07-28 2025-03-31 에이씨 이뮨 에스에이 신규 화합물
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4568975A1 (en) * 2022-08-10 2025-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
WO2024064245A1 (en) 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) * 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4612150A1 (en) * 2022-10-31 2025-09-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
EP4611743A1 (en) * 2022-11-02 2025-09-10 Merck Sharp & Dohme LLC Triazines useful as inhibitors of nod-like receptor protein 3
WO2024094150A1 (en) * 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
EP4613749A1 (en) 2022-11-04 2025-09-10 TransThera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
WO2024099996A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
WO2024099993A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
WO2024099992A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
AR131278A1 (es) * 2022-12-07 2025-03-05 Hoffmann La Roche Compuestos novedosos
CN120513236A (zh) * 2022-12-23 2025-08-19 纽摩拉治疗公司 Nlrp3炎症小体的调节剂和相关产品以及方法
TW202432558A (zh) * 2022-12-27 2024-08-16 大陸商正大天晴藥業集團股份有限公司 一種噠嗪稠芳環化合物及其用途
UY40587A (es) 2022-12-28 2024-07-31 Astrazeneca Ab Inhibidores del inflamasoma nlrp3
EP4642763A1 (en) 2022-12-28 2025-11-05 Astrazeneca AB Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds
KR20250106322A (ko) 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
AU2024206808A1 (en) * 2023-01-03 2025-07-17 Kodiak Sciences Inc. Organic compounds as nlrp3 inhibitors
WO2024148148A1 (en) * 2023-01-04 2024-07-11 The Trustees Of Columbia University In The City Of New York Pyridazine based small molecule inhibitor of cognitive impairment
EP4656635A1 (en) 2023-01-24 2025-12-03 Daiichi Sankyo Company, Limited Substituted benzene compound
KR20250137706A (ko) * 2023-01-27 2025-09-18 므윈길 테라퓨틱스 인코포레이티드 Nlrp3 억제제
WO2024160693A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
AU2024214354A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv PYRROLO[1,2-d][1,2,4]TRIAZINES AND PYRAZOLO[1,5-d] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS
CN120981460A (zh) 2023-01-31 2025-11-18 詹森药业有限公司 作为NLRP3抑制剂的[1,2,4]三唑并[4,3-a]吡啶和[1,2,4]三唑并[4,3-a]吡嗪
CN120957980A (zh) 2023-01-31 2025-11-14 詹森药业有限公司 作为nlrp3抑制剂的2-(哒嗪-3-基)-5-(三氟甲基)苯酚
CN120981462A (zh) 2023-01-31 2025-11-18 詹森药业有限公司 咪唑并[1,2-d][1,2,4]三嗪作为NLRP3抑制剂
WO2024169895A1 (zh) 2023-02-14 2024-08-22 深圳众格生物科技有限公司 一种抑制nlrp3的化合物及制备方法和应用
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
AR132817A1 (es) 2023-06-02 2025-07-30 Merck Sharp & Dohme Llc Heterociclos bicíclicos 5,6 insaturados útiles como inhibidores de la proteína receptora 3 similar a nod
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
TW202506132A (zh) * 2023-08-11 2025-02-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3炎症小體抑制劑及其應用
KR20250030934A (ko) 2023-08-25 2025-03-05 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025128777A1 (en) 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Indazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2025229146A1 (en) * 2024-05-02 2025-11-06 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor
WO2025232839A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2025252163A1 (zh) * 2024-06-07 2025-12-11 康百达（四川）生物医药科技有限公司 一种哒嗪并环衍生物及其在医药上的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510997A1 (fr) 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
FR2663326B2 (fr) 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CN1984904A (zh) 2004-05-08 2007-06-20 神经能质公司 3－芳基－5,6－二取代哒嗪
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2491050A2 (en) 2009-10-20 2012-08-29 Novartis AG Glycoside derivative and uses thereof
DK2975042T3 (en) 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
SG187796A1 (en) 2010-08-10 2013-03-28 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
LT2786996T (lt) 2011-11-29 2017-01-10 Ono Pharmaceutical Co., Ltd. Purinono darinio hidrochloridas
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
BR112015012312A2 (pt) 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EA028756B1 (ru) 2013-04-25 2017-12-29 Бэйджин, Лтд. Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
KR102350357B1 (ko) 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
JP2016540053A (ja) 2013-12-05 2016-12-22 アセルタ ファーマ ビー．ブイ． Ｐｉ３ｋ阻害剤とｂｔｋ阻害剤の治療的組み合わせ
DK3083564T3 (en) 2013-12-20 2018-10-22 Novartis Ag Heteroberl butyric acid derivatives as LTA4H inhibitors
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
TWI662039B (zh) 2014-05-13 2019-06-11 瑞士商諾華公司 用於誘發軟骨生成之化合物及組合物
CN103965169A (zh) 2014-05-30 2014-08-06 彭正中 一种化合物及其制备方法与用途
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
KR102030305B1 (ko) 2014-10-24 2019-10-08 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
EA036351B1 (ru) 2014-12-24 2020-10-29 Принсипиа Биофарма Инк. Твердая пероральная лекарственная форма для ингибирования btk и способы лечения
BR112017015273A2 (pt) 2015-01-20 2018-01-09 Merial Inc. compostos e composições antihelmínticos e método de utilizações dos mesmos
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
JP6884102B2 (ja) * 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
ES2777626T3 (es) 2015-02-16 2020-08-05 Univ Queensland Sulfonilureas y compuestos relacionados y uso de los mismos
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
PE20180521A1 (es) 2015-06-03 2018-03-14 Principia Biopharma Inc Inhibidores de tirosina-cinasas
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
EP4014977A1 (en) 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
PL3386511T3 (pl) * 2015-12-10 2021-11-08 Ptc Therapeutics, Inc. Sposoby leczenia choroby huntingtona
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR102688907B1 (ko) 2016-01-05 2024-07-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법
CA3011465A1 (en) 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
SG11202000248UA (en) 2017-07-14 2020-02-27 Innate Tumor Immunity Inc Nlrp3 modulators
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
RU2020110219A (ru) * 2017-08-15 2021-09-17 Инфлазоум Лимитед Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
EP3688187A4 (en) 2017-09-25 2021-09-29 Skyhawk Therapeutics, Inc. PROCEDURES AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPICE MODULATORS
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
AU2018363771A1 (en) * 2017-11-09 2020-05-14 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3781564B1 (en) 2018-04-10 2023-08-23 Skyhawk Therapeutics, Inc. Pyridazine derivatives for the treatment of cancer
JP7387630B2 (ja) 2018-04-26 2023-11-28 オーリジーン オンコロジー リミテッド Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021193897A1 (ja) 2020-03-27 2021-09-30 アステラス製薬株式会社 置換ピリダジン化合物
CN116390914A (zh) 2020-12-25 2023-07-04 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
US20240166610A1 (en) 2021-02-08 2024-05-23 Medshine Discovery Inc. Substituted pyridazine phenol derivatives

Also Published As

Publication number Publication date
IL287042B2 (en) 2025-02-01
US20250270188A1 (en) 2025-08-28
ECSP21080740A (es) 2021-12-30
CN113784957A (zh) 2021-12-10
SG11202111029PA (en) 2021-12-30
CL2021003012A1 (es) 2022-09-09
IL287042B1 (en) 2024-10-01
ZA202107444B (en) 2024-11-27
CN119732956A (zh) 2025-04-01
MY206068A (en) 2024-11-27
TWI874398B (zh) 2025-03-01
US11254653B2 (en) 2022-02-22
CA3138226A1 (en) 2020-11-26
US12139471B2 (en) 2024-11-12
PH12021552885A1 (en) 2022-07-25
US11208399B2 (en) 2021-12-28
KR20220008887A (ko) 2022-01-21
CO2021015030A2 (es) 2021-11-30
AU2020277738A1 (en) 2021-11-18
CR20210552A (es) 2021-11-26
MX2021013941A (es) 2022-03-11
IL287042A (en) 2021-12-01
US20200361898A1 (en) 2020-11-19
AR119731A1 (es) 2022-01-05
AU2020277738B2 (en) 2023-03-02
TW202110809A (zh) 2021-03-16
CN113784957B (zh) 2025-02-28
JP2025004014A (ja) 2025-01-14
EP3969441A1 (en) 2022-03-23
US20220251067A1 (en) 2022-08-11
CU20210094A7 (es) 2022-06-06
JP2022532354A (ja) 2022-07-14
BR112021022796A2 (pt) 2022-04-12
SA521430853B1 (ar) 2024-08-05
JOP20210307A1 (ar) 2023-01-30
WO2020234715A1 (en) 2020-11-26
JP7558975B2 (ja) 2024-10-01
UY38687A (es) 2023-05-15
US20200361899A1 (en) 2020-11-19
DOP2021000228A (es) 2021-12-15

Similar Documents

Publication Publication Date Title
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
AR116604A1 (es) Inhibidores de kras g12c
PE20170682A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
AR060562A1 (es) Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
PE20090984A1 (es) Inhibidores de peptido desformilasa
PE20252677A1 (es) Amidas de azolipiridina piridazinona como inhibidores de sos1
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
PE20211770A1 (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que las comprenden
PH12021551692A1 (en) Novel substituted sulfonylurea derivatives
PE20211054A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2020002550A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.
PE20251255A1 (es) Inhibidores de inflamasoma nlrp3
PE20170949A1 (es) Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)